Back to Results
First PageMeta Content
Melanoma / Organochlorides / Organofluorides / Sulfonamides / Vemurafenib / BRAF / Selumetinib / Protein kinase inhibitor / Erlotinib / Chemistry / Organic chemistry / Medicine


NCI Workshop: Defining Clinical Utility of Molecular Diagnostics for Cancer Treatment
Add to Reading List

Document Date: 2013-01-24 12:59:57

Open Document

File Size: 467,50 KB

Share Result on Facebook

Company

Genentech Inc. / Molecular Response LLC / Roche Molecular Systems Inc. / Genzyme / UNC Labs / /

Country

United States / /

Event

FDA Phase / /

Facility

Laboratory Developed Tests Lack / /

IndustryTerm

Cancer Treatment / Cancer Care / /

MedicalCondition

melanoma / Cancer / tumors / NSCLC / mutation-positive metastatic Months BRIM3 melanoma / BRAFV600E mutation-positive melanoma / wild-type BRAF melanoma / metastatic melanoma / /

Organization

FDA / /

Person

Arch Pathol Lab Med / /

Position

physician / VP Global Research Roche Molecular Diagnostics / /

Product

Inh / Dacarbazine / V600 / BRIM2 / BRAFV600E / BRAF / /

ProvinceOrState

Indiana / /

URL

http /

SocialTag